Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union

Lupin receives “A-” leadership rating from CDP in climate change and water security

This rating reflects Lupin's leadership in environmental transparency and performance

EyeQ upgrades eye care facility in Surat

Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

Dr. Prabhavathi. R joins HEJJE

Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders

Nectar Life Care launches affordable anti-diabetic range of medicines

Offers affordable, high-quality solutions for diabetes care

Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients

Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab

Lupin Q3 FY25 profit up 40% at Rs. 855 Cr

Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24